Interview with Margaret Hamburg

FDA Commissioner Margaret Hamburg talks about her experience as Commissioner of the FDA.

Read More

2014 Conference on Clinical Cancer Research

Friends of Cancer Research and the Engelberg Center for Health Care Reform at Brookings co-hosted discussions on critical issues in cancer care.

Read More

New collaborative clinical trial launches

Researchers, drug developers, and patient advocates share their thoughts about Lung-MAP

Read More

Accelerating Science and Technology

Friends of Cancer Research is our country's leading voice in advocating for policies and solutions that will get treatments to patients in the safest and quickest way posible.

Read More

Breakthrough Therapies In Action

The FDA's Breakthrough Therapy program continues to accelerate the development and approval of groundbreaking new therapies.

Read More

Download the 2013 Annual Report

Friends of Cancer Research's 2013 Annual Report is now available for download.

Read More

Friends Hosts Breakthrough Briefing

Patients, drug developers, and regulators discussed Breakthrough Therapy's progress at our May briefing

Read More

Breakthrough Designations

View More

EBV-CTL - (Atara)

for the treatment of patients with rituximab-refractory, EBV-associated lymphoproliferative disease


Ibalizumab (TMB355) - (TaiMed)

for the treatment of HIV


Rindopepimut (Rintega) - (Celldex)

for the treatment of adult patients with EGFRvIII-positive glioblastoma (GBM)

Recent Blogs

FDA Commissioner Dr. Margaret Hamburg discussed her experience working with the FDA.


"There isn't a day where I'm not overwhelmed by how many people are dealing with this disease, and that's what drives all of our work at Friends of Cancer Research."

Ellen Sigal,
Chair, Friends of Cancer Research